Erschienen in:
01.08.2014 | Astute Clinician Report
SCIg vs IVIg: Let’s Give Patients the Choice!
verfasst von:
K. Samaan, M. C. Levasseur, H. Decaluwe, C. St-Cyr, H. Chapdelaine, A. Des Roches, E. Haddad
Erschienen in:
Journal of Clinical Immunology
|
Ausgabe 6/2014
Einloggen, um Zugang zu erhalten
Excerpt
Intravenous immunoglobulins (IVIg) and subcutaneous immunoglobulins (SCIg) are equally efficient in preventing serious bacterial infections (
1‐
5) in patients with primary immune deficiency (PID). Currently, SCIg or IVIG use is often based upon physician’s judgment (
2,
6). However, in some centers such as ours, patients are given the choice of treatment modality, regardless of the physician’s opinion on “idealness” of the candidate. In this retrospective study of 143 patients with PID treated by immunoglobulin (Ig) replacement, we present our experience regarding patient’s behavior when given choice of hospital-based IVIg versus home-based SCIg. …